Pharmaceutical UK biopharma company Varsity Pharmaceuticals has secured exclusive rights from Dana-Farber Cancer Institute (DFCI), a world-leading cancer treatment and research institute, to develop and commercialize novobiocin, a potential first-in-class DNA polymerase theta inhibitor for the treatment of homologous recombination (HR) deficient cancers. 8 February 2022